Breaking News Instant updates and real-time market news.

BHC

Bausch Health

$23.18

0.16 (0.70%)

13:30
04/25/19
04/25
13:30
04/25/19
13:30

Bausch Health trading resumes

  • 06

    May

  • 06

    May

  • 06

    May

BHC Bausch Health
$23.18

0.16 (0.70%)

03/19/19
RHCO
03/19/19
INITIATION
Target $30
RHCO
Buy
Bausch Health initiated with a Buy at SunTrust
SunTrust analyst Gregg Gilbert started Bausch Health with a Buy rating and $30 price target. Despite the "heavy" debt load, management is doing the right things to strengthen the business, Gilbert tells investors in a research note. He sees potential for "significant upside" for the stock over the next 12-[plus months.
03/20/19
BOFA
03/20/19
INITIATION
Target $18
BOFA
Underperform
Bausch Health initiated with an Underperform at BofA/Merrill
BofA/Merrill analyst Jason Gerberry reinstated Bausch Health with an Underperform and $18 price target. The analyst believes consensus margin expectations are overstating new pharma product launches, which are broadly a niche and highly promotional, and likely a drag on margins.
04/02/19
PIPR
04/02/19
NO CHANGE
Target $28
PIPR
Overweight
Piper 'staying bullish' on Bausch Health after headquarter visit
Piper Jaffray analyst David Amsellem is "staying bullish" on Bausch Health Companies after bring an investor group to meet with management at the company's headquarters. The analyst continues to believe that visibility into Bausch's longer-term EBITDA growth of at least in the mid-single digits is high, with key drivers including Xifaxan growth and contribution from new products. That translates into an attractive risk/reward profile at current valuation levels, Amsellem tells investors in a research note. He reiterates an Overweight rating on Bausch Health with a $28 price target.
04/10/19
MZHO
04/10/19
NO CHANGE
Target $41
MZHO
Buy
Alcon spinoff shows Bausch Health is undervalued, says Mizuho
Mizuho analyst Irina Koffler reiterates a Buy rating on Bausch Health Companies (BHC) with a $41 price target following Novartis' (NVS) spinoff of Alcon (ALC). Bausch's smaller B+L segment should trade at a "slight discount" to market leader Alcon, but calculate that the market is currently assigning only a 13 times 2019 enterprise value to EBITA multiple to the B+L business, Koffler tells investors in a research note. This highlights that Bausch Health is undervalued, contends the analyst.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.